WaveMan
WaveMan · Company
EVO · Evotec Se
> Search tickers & screens ⌘K
LIVE
← All companies

EVO Evotec (EVO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001412558
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter

EVO filings, in plain words

Read the full summary

The latest 5% ownership filing is a 13D by MAK Capital Fund LP, filed 2026-03-30, for 7.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Evotec insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Evotec SE in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch EVO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns EVO: institutional holders (13F)

13F holdings, latest reported quarter
DCF Advisers, LLC
1,079,024 sh
$3.0M
WCM INVESTMENT MANAGEMENT, LLC
671,884 sh
$1.9M
ABC ARBITRAGE SA
371,936 sh
$1.0M
Optiver Holding B.V.
322,153 sh
$902.0K
MORGAN STANLEY
205,763 sh
$576.1K

Congress trades in EVO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
MAK Capital Fund LP
Activist 13D · 2026-03-30
7.0%
MAK Capital One L.L.C.
Activist 13D · 2026-03-30
7.0%
Michael A. Kaufman
Activist 13D · 2026-03-30
7.0%

EVO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

EVO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$39.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

EVO financials

Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Gross profit$114.9M$175.1M$174.1M$151.5M
Net income-$196.1M-$83.9M-$175.7M$215.5M
SEC XBRL, fiscal years, as known on 2026-10-27

EVO Stock Sonar score 2/7 axes

Find similar shapesCompare
Institutional and government
29
Inputs
  • Funds adding, latest quarter17 · 29 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
97
Inputs
  • Short interest, % of float+0.0% · 97 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Growth, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies